

Analysis of the Apoptotic Mechanisms of Snake Venom Toxin on Inflammation–induced HaCaT Cell–line

Youl Woong Chun and Ho Sueb Song*

Department of Acupuncture & Moxibustion Medicine, College of Oriental Medicine, Gachon University



[Abstract]

Objectives : In this study, the roles of Interleukin (IL)–4 and Signal transducer and activator of transcription 6 (STAT6), which have been reported to play a role in the pathogenesis of inflammation and cancer, were evaluated in snake venom toxin (SVT)–induced apoptosis.

Methods : Inflammation was induced in human HaCaT keratinocytes, by lipopolysaccharide (LPS; 1 µg/mL) or tumor necrosis factor–α (TNF–α), followed by treatment with SVT (0, 1, or 2 µg/mL). Cell viability was assessed by MTT assays after 24 h, and the expression of levels of IL–4, STAT6, and the apoptosis–related proteins p53, Bax, and Bcl–2 were evaluated by western blotting. Electro mobility shift assays (EMSAs) were performed to evaluate the DNA binding capacity of STAT6.

Results : MTT assays showed that inflammation–induced growth of HaCaT cells following LPS or TNF–α stimulation was inhibited by SVT. Western blot analysis showed that p53 and Bax, which promote apoptosis, were increased, whereas that of Bcl–2, an anti–apoptotic protein, was decreased in a concentration–dependent manner in LPS– or TNF–α–induced HaCaT cells following treatment with SVT. Moreover, following treatment of HaCaT cells with LPS, IL–4 concentrations were increased, and treatment with SVT further increased IL–4 expression in a concentration–dependent manner. Western blotting and EMSAs showed that the phosphorylated form of STAT6 was increased in HaCaT cells in the context of LPS– or TNF–α–induced inflammation in a concentration–dependent manner, concomitant with an increase in the DNA binding activity of STAT6.

Conclusion : SVT can effectively promote apoptosis in HaCaT cells in the presence of inflammation through a pathway involving IL–4 and STAT6.

Key words :

Snake venom toxin;
Inflammation;
Apoptosis;
Interleukin–4;
Signal transducer and activator of transcription 6

Received : 2017. 01. 12.
Revised : 2017. 02. 01.
Accepted : 2017. 02. 08.
On–line : 2017. 02. 20.

* Corresponding author : Department of Acupuncture & Moxibustion Medicine, Gil Oriental Medical Hospital, 21, Keunumul–ro, Jung–gu, Incheon, Republic of Korea
Tel : +82–32–770–1342 E–mail : hssong70@gachon.ac.kr

I. Introduction

Keratinocytes are major structural components of the epidermis and participate in the initiation and/or regulation of cutaneous inflammatory and immune responses owing to their ability to produce a variety of cytokines and chemokines¹.

SVT was previously shown to act as a promising chemotherapeutic agent in the treatment many types of cancer cell, including prostate cancer cells, neuroblastoma cells, and colon cancer cells, through induction of apoptotic cell death mediated by apoptosis regulatory proteins²⁻⁵.

Apoptosis of keratinocyte is a key mechanism protecting against squamous cell carcinoma through removal of premalignant cells that have acquired mutations. In the skin, different apoptotic programs are needed to regulate cells other than melanocytes. The relative deficiency of apoptotic inhibitors in keratinocytes may function to maintain a low apoptotic threshold, as is required to sustain rapid turnover and efficiently remove damaged cells⁶.

In patients with atopic dermatitis (AD), the skin produces interleukin (IL)-4, which plays a pivotal role in inducing proliferation and differentiation into T-helper 2 (Th2) cells and promoting IgE production as a major isotype switching regulator^{7,8}. The known functions of IgE antibodies in allergic inflammation suggest that IgE and IgE-mediated mast cell and eosinophil activation contribute to AD⁹.

Therefore, in present study, the effects of SVT on the inhibition of inflammation and promotion of apoptosis were evaluated in inflammation-induced HaCaT cells, and the roles of IL-4 and signal transducer and activator of transcription 6 (STAT6) in this process were assessed.

II. Materials and Methods

1. Materials

SVT from *Vipera lebetina turanica* was purchased from Sigma (St. Louis, MO, USA). HaCaT human keratinocytes were obtained from the American Type Culture Collection (Cryosite, Lane Cove NSW, Australia). Lipopolysaccharide (LPS) and tumor necrosis factor (TNF)- α were purchased from Sigma-Aldrich (St. Louis, MO).

The specific antibodies used in western blot analysis were purchased from companies as indicated below. All other reagents were purchased from Sigma unless otherwise stated.

Bcl-2 (1:1,000 dilution) were purchased from Cell Signaling Technology (Beverly, MA), Bax, STAT6 and p-STAT6 (1:1,000 dilution) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and IL-4 (1:1,000 dilution) were purchased from Thermo Fisher (Waltham, MA).

2. Cell culture

HaCaT cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies, Grand Island, NY) with 10% fetal bovine serum, 100 U/ mL penicillin and 100 μ g/mL streptomycin at 37°C in 5% CO₂ humidified. All cells were cultured in 24-well plates from Costar. RPMI 1640, MEM α , penicillin, streptomycin, and FBS were purchased from Gibco Life Technologies (Grand Island, NY).

3. Cell viability assay

To determine viable cell numbers, HaCaT human keratinocytes were seeded onto 24-well plates (5 \times 10⁴ cells/well), and subconfluent cells were subsequently treated with snake venom (0-2 μ g/mL) for 24 h. The cells were trypsinized,

pelleted by centrifugation for 5 min at 1500 rpm, and resuspended in 10 mL phosphate-buffered saline (PBS). Subsequently, 0.1 mL of 0.2% trypan blue was added to each cell suspension (0.9 mL). Subsequently, a drop of each suspension was placed in a Neubauer chamber, and the number of HaCaT cells was counted. Cells that showed signs of trypan blue uptake were considered to be dead, whereas those that excluded trypan blue were considered to be viable. Each assay was carried out in triplicate.

4. Western blot analysis

Cells were homogenized with lysis buffer (50 μ M Tris, pH 8.0, 150 μ M NaCl, 0.02% NaN_3 , 0.2% sodium dodecyl sulfate [SDS], 1 μ M phenylmethylsulfonyl fluoride, 10 μ L/mL aprotinin, 1% igaprel 630 [Sigma], 10 μ M NaF, 0.5 μ M ethylenediaminetetraacetic acid [EDTA], 0.1 μ M EGTA, and 0.5% sodium deoxycholate) and centrifuged at $23,000 \times g$ for 1 h. Equal amounts of proteins (80 μ g) were separated on 12% SDS-polyacrylamide gels and then transferred to a nitrocellulose membranes (Hybond ECL; Amersham Pharmacia Biotech). Blots were blocked for 2 h at room temperature with 5% (w/v) nonfat dried milk in Tris buffered saline (10 μ M Tris, pH 8.0, 150 μ M NaCl) containing 0.05 % Tween 20. The membranes were then incubated for 5 h at room temperature with the following specific antibodies: Bcl-2 (1:1,000 dilution; Cell Signaling Technology), Bax, STAT6 and p-STAT6 (1:1,000 dilution; Santa Cruz Biotechnology) and IL-4 (1:1,000 dilution; Thermo Fisher). Blots were then incubated with corresponding anti-rabbit and anti-mouse immunoglobulin G- secondary antibodies conjugated with horseradish peroxidase (1:2,000 dilution; Santa Cruz Biotechnology). Immunoreactive proteins were detected with an ECL western blotting detection system.

5. Electro mobility shift assay (EMSA)

The DNA binding activity of STAT6 was determined using EMSAs (Promega) according to the manufacturer's recommendations. Nuclear extracts were prepared and processed for EMSA as previously described¹⁰. The relative densities of the DNA/protein binding bands were scanned by densitometry using MyImage (SLB), and quantified by Labworks 4.0 software (UVP, Inc., Upland, CA).

6. Statistical analysis

The data were analyzed using the GraphPad Prism 4 ver. 4.03 software (Graph-Pad Software, La Jolla, CA). Data are presented as means \pm standard deviations (SDs). Differences in all data were assessed by one-way analysis of variance (ANOVA). When the *p* value obtained from ANOVA indicated statistical significance, the differences were further assessed by Dunnett's tests. *p* values of 0.05 or less were considered statistically significant.

III. Results

1. Effects of SVT on the growth of HaCaT cells in the context of LPS-induced inflammation

To assess the inhibitory effects of SVT in the presence of LPS (1 μ g/mL) on cell growth of human HaCaT keratinocytes, cell viability was analyzed by MTT assay. The treatment of LPS inhibited the HaCaT cells growth. The cells were treated with two concentrations of SVT (1 and 2 μ g/mL) for 24 h in the presence of LPS. SVT augmented LPS-induced inhibition of cell growth of HaCaT cells (Fig. 1).




Fig. 1. Effects of SVT on the viability of HaCaT cells

Human HaCaT keratinocytes were treated with lipopolysaccharide (LPS; 1 μg/mL) with or without snake venom toxin (SVT). After treatment, cell viability was measured by MTT assay.

#: $p < 0.05$ versus the control group.

*: $p < 0.05$ versus the LPS-treated group.

2. Effects of SVT on the growth of HaCaT cells in the context of TNF-α-induced inflammation

To assess the inhibitory effects of SVT in the presence of TNF-α on cell growth in human HaCaT keratinocytes, cell viability was analyzed by MTT assays. Treatment with TNF-α inhibited HaCaT cell growth. Cells were then treated with two concentrations of SVT (1 or 2 μg/mL) for 24 h in the presence of TNF-α. The results showed that SVT augmented TNF-α-induced inhibition of cell growth in HaCaT cells (Fig. 2).

3. Apoptotic effects of SVT on HaCaT cells in the context of LPS-induced inflammation

To evaluate apoptotic cell death in response to SVT under atopic conditions induced by LPS *in vitro*, western blot analysis was performed in HaCaT cells. LPS was used to induce atopic conditions in HaCaT cells. Expression levels of IL-4 and pro-apoptotic proteins, such as p53 and Bax, were increased, whereas the expression of anti-apoptotic Bcl-2 was significantly decreased follow-




Fig. 2. Effects of SVT on the viability of TNF-α-treated HaCaT cells

Human HaCaT keratinocytes were treated with tumor necrosis factor-α (TNF-α; 10 ng/mL) with or without snake venom toxin (SVT). After treatment, cell viability was measured by MTT assay.

#: $p < 0.05$ versus the control group.

*: $p < 0.05$ versus the TNF-α-treated group.

ing treatment with LPS or SVT (1 or 2 μg/mL) in a concentration-dependent manner (Fig. 3).

4. Apoptotic effects of SVT on HaCaT cells in the context of TNF-α-induced inflammation

To evaluate apoptotic cell death in response to SVT under atopic conditions induced by TNF-α *in vitro*, blot analysis was performed in HaCaT cells. TNF-α was used to induce atopic conditions in HaCaT cells. Expression levels of IL-4, p53, and Bax were significantly enhanced, whereas Bcl-2 expression was decreased by the treatment with TNF-α or SVT (1 and 2 μg/mL) in a concentration-dependent manner (Fig. 4).

5. Effects of SVT on LPS-induced STAT6 activation in HaCaT cells

To investigate whether SVT affected LPS-induced STAT6 activation, EMSAs were used to detect the DNA binding activity of STAT6. The results showed that LPS-treated HaCaT cells showed low constitutive activation of STAT6. How-




Fig. 3. Apoptotic effects of SVT on HaCaT cells in the context of LPS-induced inflammation

HaCaT cells were treated with lipopolysaccharide (LPS; 1 μ g/mL) with or without snake venom toxin (SVT). After treatment, the expression of apoptosis regulatory proteins was determined. β -Actin was used an internal control. Each blot is representative of three experiments.




Fig. 4. Apoptotic effects of SVT on HaCaT cells in the context of TNF- α -induced inflammation

HaCaT cells were treated with tumor necrosis factor- α (TNF- α ; 10 ng/mL) with or without snake venom toxin (SVT). After treatment, the expression of apoptosis regulatory proteins was determined. β -Actin was used an internal control. Each blot is representative of three experiments.

ever, treatment with SVT enhanced LPS-induced DNA binding activity of STAT6 in a concentration-dependent manner (Fig. 5). Consistent with these findings, the phosphorylation of STAT6 in the nucleus was enhanced by SVT treatment in LPS-induced HaCaT cells (Fig. 5).

6. Effects of SVT on TNF- α -induced STAT6 activation in HaCaT cells

To investigate whether SVT affected TNF- α -induced STAT6 activation, EMSAs were performed to




Fig. 5. Effects of SVT on LPS-induced STAT6 activation in HaCaT cells

Signal transducer and activator of transcription 6 (STAT6) activity was detected by electromobility shift assays (EMSAs). The levels of STAT6 and phospho-STAT6 (p-STAT6) were detected by western blotting using specific antibodies. Histone protein was used an internal control. Each blot is representative of three experiments.




Fig. 6. Effects of SVT on TNF- α -induced STAT6 activation in HaCaT cells

Signal transducer and activator of transcription 6 (STAT6) activity was detected by electromobility shift assays (EMSA). The levels of STAT6 and phospho-STAT6 (p-STAT6) were detected by western blotting using specific antibodies. Histone protein was used an internal control. Each blot is representative of three experiments.

detect the DNA binding activity of STAT6. The results showed that TNF- α -induced HaCaT cells showed low constitutive activation of STAT6. However, treatment with SVT enhanced the TNF- α -induced DNA binding activity of STAT6 in a concentration-dependent manner (Fig. 6). Consistent with these findings, the phosphorylation of STAT6 in the nucleus was enhanced by SVT treatment in TNF- α -induced HaCaT cells (Fig. 6).

IV. Discussion

In this study, the results showed that SVT was effective for reducing cell growth in human HaCaT cells under inflammatory conditions based on the observation that SVT inhibited the growth of inflammation-induced HaCaT cells, enhanced cytotoxicity through the increased expression of IL-4 and STAT6, and activated apoptosis by regulating the activities of pro-apoptotic p53, pro-apoptotic Bax, and anti-apoptotic Bcl-2 simultaneously.

LPS has been shown to inhibit the extracellular membrane of gram-negative bacteria. As an endo-

toxin, LPS stimulates the expression of inducible nitric oxygen synthase (iNOS), which produces inflammatory cytokines, such as TNF- α , IL-6, and IL-1, as well as the inflammatory mediator nitric oxide (NO), in macrophages. In particular, TNF- α is secreted as an important stimulator of for the early inflammatory response and then induces the expression of IL-6 and IL-8, leading to a series of inflammatory responses¹¹.

IL-4 has been shown to induce IgE production in B cells and to be secreted by Th2 cells¹². Moreover, IL-4 plays a key role in allergic inflammation. Divergent effects of IL-4 have been reported in hematopoietic cells, fibroblasts, and epithelial cells. In the monocyte/macrophage lineage, IL-4 displays anti-inflammatory properties, e.g., inhibition of LPS-induced IL-1 β , TNF- α , and IL-10 production. In particular, IL-4 regulates TNF- α -induced transcription of IL-8, a CXC chemokine induced by pro-inflammatory cytokines, such as TNF- α , IL-1 β , and IL-6, in different cell types, including keratinocytes; this mechanism involves STAT6 and nuclear factor (NF)- κ B. Binding of IL-4 to its receptor leads to activation of the Janus kinase (JAK)/STAT signal transduction pathway¹. IL-8 signaling increases the proliferation and sur-

vival of endothelial and cancer cells and promotes the migration of cancer cells, endothelial cells, and infiltrating neutrophils at the tumor site. Therefore, inhibiting the effects of IL-8 signaling may be an important therapeutic intervention in the targeting of the tumor microenvironment¹³.

The tumor-suppressor p53 is an anticancer gene that functions to regulate Bcl-2 and Bax gene expression *in vitro* and *in vivo*, thereby inhibiting abnormal cell proliferation and inducing the death of cancer cells through modulation of apoptosis, via regulating the ratio of pro-apoptotic bax and anti-apoptotic bcl-2, a vital tumor suppressive process¹⁴⁻¹⁶. The most intuitive link between p53-mediated transactivation and apoptosis is based on its ability to control the transcription of pro-apoptotic members of the Bcl-2 family, including Bcl-2, Bax, and Bak; their net effect is to increase the ratio of pro-apoptotic to anti-apoptotic Bcl-2 proteins, thereby favoring the release of apoptogenic proteins from the mitochondria, promoting caspase activation, and enhancing apoptosis¹⁶.

AD-like conditions, including inflammation, were induced by LPS or TNF- α in this study. The results showed that IL-4 inhibited TNF- α -induced IL-8 through activation of the JAK/STAT pathway in HaCaT cells¹ and that SVT significantly inhibited LPS- or TNF- α -induced inflammation in HaCaT cells in a concentration-dependent manner compared with that in the control (Figs. 1, 2). The expression levels of IL-4, p53, and Bax were significantly increased in LPS- and TNF- α -induced keratinocytes depending on the concentration of SVT, whereas Bcl-2 expression was decreased (Figs. 3, 4). In HaCaT cells, expression of apoptotic regulators, such as Bcl-2 and Bax, is absent or barely detectable; however, p53 expression is strong⁶. According to the results of this study, in addition to enhancing the expression of p53, SVT enhanced Bax expression and suppressed Bcl-2 expression, suggesting that SVT promoted apoptosis.

Treatment with SVT enhanced the LPS- and TNF- α -induced DNA binding activity STAT6 in a

concentration-dependent manner, and levels of phosphorylated STAT6 were also increased (Figs. 5, 6). These data indicated that IL-4 was associated with STAT6 and that SVT promoted the apoptosis of HaCaT cells under inflammatory conditions.

In conclusion, the effects of SVT on inflammatory keratinocytes were evaluated *in vitro*, and the results showed that SVT could promote apoptosis, causing rapid turnover and removing damaged cells in the skin. Although further studies using squamous cell lines *in vitro* or animal experiments *in vivo* are needed to confirm the results of this study, these findings provide new insights into the application of SVT as a preventive intervention in the management of squamous cell carcinoma.

V. References

1. J. Raingeaud, J. Pierre. Interleukin-4 down-regulates TNF α -induced IL-8 production in keratinocytes. *FEBS Letter*. 2005;579:3953-9.
2. Kim KT, Song HS. Inhibitory Effect of Snake Venom Toxin on Colorectal Cancer HCT116 Cells Growth through Induction of Intrinsic or Extrinsic Apoptosis. *The Acupunct*. 2013;30(1): 43-55.
3. Son DJ, Park MH, Chae SJ et al. Inhibitory effect of SVT from *Vipera lebetina turanica* on hormone-refractory human prostate cancer cell growth: Induction of apoptosis through inactivation of nuclear factor kappaB. *Mol Cancer Ther*. 2007;6:675-83.
4. Park MH, Son DJ, Kwak DH et al. Snake venom toxin inhibits cell growth through induction of apoptosis in neuroblastoma cells. *Arch Pharm Res*. 2009;32:1545-54.
5. Oh MG, Song HS. Inhibitory Effect of Snake Venom on Colon Cancer Cell Growth Through Induction of Death Receptor Dependent Apoptosis. *The Acupunct*. 2012;29(1):25-35.
6. Anneli R. Bowen, Adrienne N. Hanks, Sarah M.

- Allen, April Alexander, Miyoung J. Diedrich, Douglas Grossma. Apoptosis Regulators and Responses in Human Melanocytic and Keratinocytic Cells. *The Journal of Investigative Dermatology*. 2003;120(1):48–55.
7. Simpson CR, Anderson WJ, Helms PJ et al. Coincidence of immune-mediated diseases driven by Th1 and Th2 subsets suggests a common aetiology. A population-based study using computerized general practice data. *Clin Exp Allergy*. 2002;32(1):37–42.
 8. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. *Nat Rev Immunol*. 2003;3(9):721–32.
 9. Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. *Clin Rev Allergy Immunol*. 2011;41(3):298–310.
 10. Ko SC. Inhibitory Effect of Bee Venom Toxin on the Growth of Cervix Cancer C33A Cells via Death Receptor Expression and Apoptosis [Dissertation]. Gyeonggi: Gachon Univ. 2014. Korean.
 11. Lee KE, Nam JJ, Kim SM, Kim HK, Moon SJ, Youm JK. Anti-Inflammatory Effects of the Mixture of *Sorbus commixta*, *Urtica dioica*, *Phyllostachys nigra*, and *Rhus semialata* Gall Extracts on LPS-induced Inflammation in HaCaT Cells. *J. Soc. Cosmet. Scientists Korea*. 2014;40(1):45–54.
 12. May R.D, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. *Cytokine*. 2015;75:89–116.
 13. David J.J. Waugh, Catherine W. The Interleukin-8 Pathway in Cancer. *Clin Cancer Res*. 2008;14(21):6735–41.
 14. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. *Oncogene*. 1994;9(6):1799–805.
 15. The Korean society of Pathologist. *Textbook of Pathology*. Seoul: KMS. 2010:22–7.
 16. Jordan S Fridman, Scott W Lowe. Control of apoptosis by p53. *Oncogene*. 2003;22:9030–40.